Epithelial ovarian cancer continues to challenge clinicians.
There is no accepted method of screening for ovarian cancer, and most patients present with advanced disease.
In spite of advances in surgery and chemotherapy, survival continues to be poor.
The data, comprising the ovarian cancer caseloads of 940 hospitals, are from the National Cancer Data Base.
The 15,254 patients, diagnosed in 1988 or 1993, had no prior cancer diagnosis.
Data quality had improved by 1993 ; 89.4% of the records included American Joint Committee on Cancer (AJCC) staging information in 1993, compared with 67.9% in 1988.
Borderline epithelial tumors and germ cell tumors were most commonly found in younger women and were more likely to be diagnosed at Stage I. The percentage of women with carcinoma treated only with surgery increased substantially by 1993.
Relative survival decreased with increasing tumor stage or grade.
Five-year survival was considerably lower for women with carcinoma (38%) than for women with either borderline carcinoma (95%) or germ cell tumors (86%). The addition of chemotherapy to the treatment of Stage I carcinoma did not improve outcome, nor was dramatic improvement in survival brought about by the addition of chemotherapy to the treatment of Stage II and III low grade disease.
Chemotherapy was beneficial to patients with Stage II or III disease, Grade 3 or 4, and Stage IV disease.
Mots-clés Pascal : Tumeur maligne, Ovaire, Modalité traitement, Pronostic, Survie, Epidémiologie, Echelon national, Etats Unis, Amérique du Nord, Amérique, Homme, Femelle, Appareil génital femelle pathologie, Ovaire pathologie
Mots-clés Pascal anglais : Malignant tumor, Ovary, Application method, Prognosis, Survival, Epidemiology, National scope, United States, North America, America, Human, Female, Female genital diseases, Ovarian diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0013336
Code Inist : 002B20C02. Création : 21/05/1997.